News

PARP, or poly (ADP-ribose) polymerase, is a DNA repair protein that restores single strand DNA breaks and by inhibiting PARP, certain cancer cells may be rendered unable to

The trial will evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Lilly’s vascular endothelial growth factor (VEGF) Receptor 2

Argatroban Injection is an anticoagulant indicated for prophylaxis or treatment of thrombosis in adult patients with heparin induced thrombocytopenia (HIT), or as an anticoagulant in adult patients with

Results from the Phase 3 PALOMA-3 study will be featured today in a press briefing during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)

Cerdulatinib is an oral, dual Syk-JAK kinase inhibitor that Portola is developing to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded

The data included in the MAA support the use of F/TAF to treat HIV-1 infection in adults in combination with other HIV antiretroviral agents. TAF is a new

Cannabics’ team of scientists has developed a high throughput screening system which is specifically designed to give personalized antitumor treatments to cancer patients. In this proprietary system, biopsies

Ace-ER is designed to replace the deficient sialic acid substrate in patients with GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), a rare, progressive muscle-wasting disease.

In an effort to improve the quality of life for patients suffering from this debilitating disorder, a research team of investigators at Boehringer Ingelheim, the Universities of Michigan